Physician profile
Beth D Reid
NPI 1619975430
$2,450.27
in general payments reported to CMS, 2019-2025
26 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.31 · 2020: $271 · 2021: $425 · 2022: $513 · 2023: $492 · 2024: $306 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.23 |
| Education | $146.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $374.06 | 2022-2025 | |
| Abbvie INC. | $297.83 | 2019-2023 | |
| Millicent US INC | $206.06 | 2023-2025 | Femring, Intrarosa |
| Astellas Pharma US INC | $183.64 | 2021-2023 | Myrbetriq, Veozah |
| Therapeuticsmd, INC. | $179.68 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $156.86 | 2023-2025 | Myfembree, Gemtesa |
| Agile Therapeutics, INC. | $136.36 | 2021-2023 | Twirla |
| Exeltis, USA INC. | $119.76 | 2021-2025 | Slynd |
| Avion Pharmaceuticals | $97.89 | 2020-2023 | Balcoltra |
| Organon LLC | $97.65 | 2022-2024 | Nexplanon |
| Intuitive Surgical, INC. | $85.71 | 2020 | |
| Biogen, INC. | $84.58 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $81.10 | 2020-2025 | Paragard T 380a |
| Pfizer INC. | $63.53 | 2024-2025 | |
| Myovant Sciences INC. | $61.24 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $36.93 | 2019 | |
| Shield Therapeutics INC | $35.88 | 2023 | Accrufer |
| Urovant Sciences INC | $33.52 | 2021-2022 | |
| Aspira Women'S Health INC | $25.33 | 2020-2024 | Ova1 |
| Dexcom, INC. | $21.43 | 2025 | Dexcom G6 Transmitter |
| Axonics, INC. | $20.03 | 2021 | |
| Mimedx Group, INC. | $15.92 | 2024 | |
| Mylan Pharmaceuticals INC. | $13.80 | 2021 | |
| Mission Pharmacal Company | $11.93 | 2021 | |
| Evofem Biosciences, INC. | $9.55 | 2025 | Solosec, Phexx, Phexxi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.